OncoMatch/Clinical Trials/NCT04483076
Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
Is NCT04483076 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Chemotherapy drug for gastric cancer.
Treatment: Chemotherapy drug — RESONANCE-II trial is a prospective, multicenter, randomized, controlled phase III study which will enroll 524 patients in total. Patients with eligibility will be registered, pre-enrolled and receive three cycles of SOX. Then, tumor response evaluation will be carried out. Those who achieve stable disease or progressive disease will be excluded. Patients achieving complete response or partial response will be enrolled and assigned into either group A for another three cycles of SOX (six cycles in total) followed by D2 surgery and group B for D2 surgery (three cycles in total). The primary endpoint is the rate of pathological complete response and the secondary endpoints are R0 resection rate, three-year disease-free survival, five-year overall survival and safety.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Received any chemotherapy, radiotherapy or immunotherapy before
Cannot have received: radiotherapy
Received any chemotherapy, radiotherapy or immunotherapy before
Cannot have received: immunotherapy
Received any chemotherapy, radiotherapy or immunotherapy before
Lab requirements
Blood counts
hemoglobin (Hb) ≥ 90 g/L, neutrophil absolute count ≥ 3×10^9 /L, platelet count (PLT) ≥ 100×10^9 /L, serum albumin (ALB) ≥ 30 g/L
Kidney function
serum creatinine (SCr) ≤ 1.5×ULN
Liver function
ALT and AST ≤ 2.5 times the upper limit of normal (ULN), total bilirubin ≤ 1.5×ULN
Cardiac function
left ventricular ejection fraction ≥ 50%, ECG basically normal within 4 weeks before operation and without obvious symptoms
Laboratory test criteria: peripheral blood hemoglobin (Hb) ≥ 90 g/L, neutrophil absolute count ≥ 3×10^9 /L, platelet count (PLT) ≥ 100×10^9 /L, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times the upper limit of normal (ULN), total bilirubin ≤ 1.5×ULN, serum creatinine (SCr) ≤ 1.5×ULN, and serum albumin (ALB) ≥ 30 g/L; Patients with heart disease, the echocardiogram showed that the left ventricular ejection fraction ≥ 50%, the electrocardiogram (ECG) is basically normal within 4 weeks before operation and without no obvious symptoms are acceptable
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify